Cargando…
Identification of drug combinations administered by continuous subcutaneous infusion that require analysis for compatibility and stability
BACKGROUND: A continuous subcutaneous infusion (CSCI) delivered via syringe pump is a method of drug administration used to maintain symptom control when a patient is no longer able to tolerate oral medication. Several classes of drugs, such as opioids, antiemetics, anticholinergics, antipsychotics...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5364569/ https://www.ncbi.nlm.nih.gov/pubmed/28335763 http://dx.doi.org/10.1186/s12904-017-0195-y |
_version_ | 1782517347213377536 |
---|---|
author | Dickman, Andrew Bickerstaff, Matthew Jackson, Richard Schneider, Jennifer Mason, Stephen Ellershaw, John |
author_facet | Dickman, Andrew Bickerstaff, Matthew Jackson, Richard Schneider, Jennifer Mason, Stephen Ellershaw, John |
author_sort | Dickman, Andrew |
collection | PubMed |
description | BACKGROUND: A continuous subcutaneous infusion (CSCI) delivered via syringe pump is a method of drug administration used to maintain symptom control when a patient is no longer able to tolerate oral medication. Several classes of drugs, such as opioids, antiemetics, anticholinergics, antipsychotics and benzodiazepines are routinely administered by CSCI alone or in combinations. Previous studies attempting to identify the most-common CSCI combinations are now several years old and no longer reflect current clinical practice. The aim of this work was to review current clinical practice and identify CSCI drug combinations requiring analysis for chemical compatibility and stability. METHODS: UK pharmacy professionals involved in the delivery of care to palliative patients in hospitals and hospices were invited to enter CSCI combinations comprised of two or more drugs onto an electronic database over a 12-month period. In addition, a separate Delphi study with a panel of 15 expert healthcare professionals was completed to identify a maximum of five combinations of drugs used to treat more complex, but less commonly encountered symptoms unlikely to be identified by the national survey. RESULTS: A total of 57 individuals representing 33 separate palliative care services entered 1,945 drug combinations suitable for analysis, with 278 discrete combinations identified. The top 40 drug combinations represented nearly two-thirds of combinations recorded. A total of 23 different drugs were administered in combination and the median number of drugs in a combination was three. The Delphi study identified five combinations for the relief of complex or refractory symptoms. CONCLUSION: This study represents the first step towards developing authoritative national guidance on the administration of drugs by CSCI. Further work will ensure healthcare practitioners have the knowledge and confidence that a prescribed combination will be both safe and efficacious. |
format | Online Article Text |
id | pubmed-5364569 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-53645692017-03-24 Identification of drug combinations administered by continuous subcutaneous infusion that require analysis for compatibility and stability Dickman, Andrew Bickerstaff, Matthew Jackson, Richard Schneider, Jennifer Mason, Stephen Ellershaw, John BMC Palliat Care Research Article BACKGROUND: A continuous subcutaneous infusion (CSCI) delivered via syringe pump is a method of drug administration used to maintain symptom control when a patient is no longer able to tolerate oral medication. Several classes of drugs, such as opioids, antiemetics, anticholinergics, antipsychotics and benzodiazepines are routinely administered by CSCI alone or in combinations. Previous studies attempting to identify the most-common CSCI combinations are now several years old and no longer reflect current clinical practice. The aim of this work was to review current clinical practice and identify CSCI drug combinations requiring analysis for chemical compatibility and stability. METHODS: UK pharmacy professionals involved in the delivery of care to palliative patients in hospitals and hospices were invited to enter CSCI combinations comprised of two or more drugs onto an electronic database over a 12-month period. In addition, a separate Delphi study with a panel of 15 expert healthcare professionals was completed to identify a maximum of five combinations of drugs used to treat more complex, but less commonly encountered symptoms unlikely to be identified by the national survey. RESULTS: A total of 57 individuals representing 33 separate palliative care services entered 1,945 drug combinations suitable for analysis, with 278 discrete combinations identified. The top 40 drug combinations represented nearly two-thirds of combinations recorded. A total of 23 different drugs were administered in combination and the median number of drugs in a combination was three. The Delphi study identified five combinations for the relief of complex or refractory symptoms. CONCLUSION: This study represents the first step towards developing authoritative national guidance on the administration of drugs by CSCI. Further work will ensure healthcare practitioners have the knowledge and confidence that a prescribed combination will be both safe and efficacious. BioMed Central 2017-03-23 /pmc/articles/PMC5364569/ /pubmed/28335763 http://dx.doi.org/10.1186/s12904-017-0195-y Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Dickman, Andrew Bickerstaff, Matthew Jackson, Richard Schneider, Jennifer Mason, Stephen Ellershaw, John Identification of drug combinations administered by continuous subcutaneous infusion that require analysis for compatibility and stability |
title | Identification of drug combinations administered by continuous subcutaneous infusion that require analysis for compatibility and stability |
title_full | Identification of drug combinations administered by continuous subcutaneous infusion that require analysis for compatibility and stability |
title_fullStr | Identification of drug combinations administered by continuous subcutaneous infusion that require analysis for compatibility and stability |
title_full_unstemmed | Identification of drug combinations administered by continuous subcutaneous infusion that require analysis for compatibility and stability |
title_short | Identification of drug combinations administered by continuous subcutaneous infusion that require analysis for compatibility and stability |
title_sort | identification of drug combinations administered by continuous subcutaneous infusion that require analysis for compatibility and stability |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5364569/ https://www.ncbi.nlm.nih.gov/pubmed/28335763 http://dx.doi.org/10.1186/s12904-017-0195-y |
work_keys_str_mv | AT dickmanandrew identificationofdrugcombinationsadministeredbycontinuoussubcutaneousinfusionthatrequireanalysisforcompatibilityandstability AT bickerstaffmatthew identificationofdrugcombinationsadministeredbycontinuoussubcutaneousinfusionthatrequireanalysisforcompatibilityandstability AT jacksonrichard identificationofdrugcombinationsadministeredbycontinuoussubcutaneousinfusionthatrequireanalysisforcompatibilityandstability AT schneiderjennifer identificationofdrugcombinationsadministeredbycontinuoussubcutaneousinfusionthatrequireanalysisforcompatibilityandstability AT masonstephen identificationofdrugcombinationsadministeredbycontinuoussubcutaneousinfusionthatrequireanalysisforcompatibilityandstability AT ellershawjohn identificationofdrugcombinationsadministeredbycontinuoussubcutaneousinfusionthatrequireanalysisforcompatibilityandstability |